BATTELLE PACIFIC NORTHWEST LABORATORIES

RICHLAND, WA

Oncologygene editingPhase II

What changed

Phase II trial registered: Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

3mo agoTrial registeredApr 6, 2026Source filing (opens the source filing in a new tab)

Momentum

74no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $677k · non-dilutive
Apr 11, 2025
STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · NCI · award ends Mar 31, 2029 · Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer
NIH RePORTER · NIH RePORTER 11091232 (opens the source filing in a new tab)
Grant
R35 · $360k · non-dilutive
Apr 3, 2025
RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI LIU, TINA Y · NIGMS · award ends Feb 28, 2030 · Exploring Diverse Mechanisms of Type III CRISPR-Cas signaling.
NIH RePORTER · NIH RePORTER 11021846 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Oct 1, 2024
Malignant Solid Neoplasm · RECRUITING · sponsor: Roswell Park Cancer Institute · Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
ClinicalTrials.gov · NCT06306638 (opens the source filing in a new tab)
Grant
R01 · $453k · non-dilutive
Sep 1, 2024
WASHINGTON UNIVERSITY · PI LIU, TA-CHIANG · NIDDK · award ends Jun 30, 2027 · Macrophage LRRK2 activity regulates gut epithelial homeostasis
NIH RePORTER · NIH RePORTER 11180313 (opens the source filing in a new tab)
Grant
R03 · $161k · non-dilutive
Aug 15, 2024
CASE WESTERN RESERVE UNIVERSITY · PI LIU, TIAN · NIA · award ends May 31, 2027 · Pathogenic Role of APP E590D in Alzheimer’s Disease.
NIH RePORTER · NIH RePORTER 11159819 (opens the source filing in a new tab)
Grant
R01 · $618k · non-dilutive
Aug 1, 2024
CASE WESTERN RESERVE UNIVERSITY · PI LIU, TIAN · NIA · award ends Apr 30, 2029 · Protective Role of Mitochondrial CHCHD10 in Alzheimer's Disease through MAM and Mitophagy Mechanisms.
NIH RePORTER · NIH RePORTER 11143673 (opens the source filing in a new tab)
Grant
R01 · $675k · non-dilutive
Mar 1, 2024
ROSWELL PARK CANCER INSTITUTE CORP · PI SHAFIRSTEIN, GAL · NCI · award ends Feb 28, 2029 · Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction
NIH RePORTER · NIH RePORTER 11043332 (opens the source filing in a new tab)
Grant
R01 · $569k · non-dilutive
Sep 1, 2023
WASHINGTON UNIVERSITY · PI LIU, TA-CHIANG · NIDDK · award ends Jun 30, 2027 · Dietary modulation of Paneth cells
NIH RePORTER · NIH RePORTER 11126742 (opens the source filing in a new tab)
Grant
U24 · $1.2M · non-dilutive
Jun 1, 2022
BATTELLE PACIFIC NORTHWEST LABORATORIES · PI LIU, TAO · NCI · award ends May 31, 2027 · Center for Advanced Multi-Omic Characterization of Cancer
NIH RePORTER · NIH RePORTER 11113839 (opens the source filing in a new tab)
Grant
R33 · $955k · non-dilutive
Apr 1, 2022
STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · NIAID · award ends May 31, 2027 · Developing a Multivalent Subunit Particle Vaccine Against Tuberculosis
NIH RePORTER · NIH RePORTER 11325904 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator LIU, TIAN is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the grant record at 0.27{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
3mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Dietary modulation of Paneth cells
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Macrophage LRRK2 activity regulates gut epithelial homeostasis
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R33 · $1.0M · Developing a Multivalent Subunit Particle Vaccine Against Tuberculosis
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH U24 · $1.2M · Center for Advanced Multi-Omic Characterization of Cancer
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R03 · $0.2M · Pathogenic Role of APP E590D in Alzheimer’s Disease.
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Protective Role of Mitochondrial CHCHD10 in Alzheimer's Disease through MAM and Mitophagy Mechanisms.
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Exploring Diverse Mechanisms of Type III CRISPR-Cas signaling.
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction
Feb 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R01 · $677k · non-dilutive

R35 · $360k · non-dilutive

PHASE1/PHASE2 registered

R01 · $453k · non-dilutive

R03 · $161k · non-dilutive

R01 · $618k · non-dilutive

R01 · $675k · non-dilutive

R01 · $569k · non-dilutive

U24 · $1.2M · non-dilutive

R33 · $955k · non-dilutive